Seqens Seqens

X
[{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centaur Pharma Launches Novel Topical Solution WoxHeal for the Treatment of Diabetic Foot Ulcer","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Podiatry","graph2":"Approved"},{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Vaxart","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KindredBio Expands Manufacturing Agreement with Vaxart","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Centaur Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            WOXheal has dual mechanism of action, i.e. it has functional antibacterial action against Gram positive and gram negative bacteria and it also promotes growth of fibroblast cells, thereby yielding complete wound closure.

            Lead Product(s): Diperoxochloric Acid

            Therapeutic Area: Podiatry Product Name: WOXheal

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 08, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The manufacturing services will be performed via Centaur Biopharmaceutical Services (Centaur), a wholly owned subsidiary of KindredBio that provides full service contract development and manufacturing services.

            Lead Product(s): VXA-CoV2-1

            Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-CoV2-1

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Vaxart

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 07, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY